IDEA AG receives two milestone payments ($37 million) from partner Alpharma - Gilde Healthcare

IDEA AG receives two milestone payments ($37 million) from partner Alpharma

May 7, 2008

IDEA AG today announced that it has received two milestone payments under the US licensing agreement with Alpharma Ireland Limited for Diractin® (ketoprofen in Transfersome®, formerly known as IDEA-033). The total payment of $37 million was triggered by IDEA’s reaching clinical as well as regulatory progress with the product.

In September 2007, IDEA AG had signed a Licensing Agreement under which the US rights were out-licensed to Alpharma Ireland and the global development responsibility and commercialisation rights to the product outside the USA were retained. IDEA simultaneously obtained an up-front fee of $60 million, and became eligible for a series of success dependent milestones, warrants in Alpharma Inc. shares, as well as royalties; the Company thus received $60 plus $37 million from its US partner to date, the next payment being due in case of a grant of US patent for Diractin®. A pan-European patent running till the end of 2023 has been issued in 2007. The product has moreover been approved by SwissMedic for the treatment with the highest dose, with an indication of “symptomatic treatment of inflammation and pain of osteoarthritis”. Furthermore, the product is under review by EMEA with a proposed indication of “symptomatic treatment of mild to moderate pain in osteoarthritis of superficial joints like the knee”

Gregor Cevc, IDEA’s founder and CEO, commented: “Almost simultaneous payment of two milestones by Alpharma indicate excellent progress with Diractin® product development. It is also a sign of a smoothly running, mutually beneficial collaboration between partners with a similar vision. Our next commercial step will be the assignment of marketing partner(s) in Europe.”

ENDS

For further information, please contact:

IDEA AG Prof. Gregor Cevc PhD, CEO
Tel.: +49 (172) 8386267

Jens Peter Wartmann, CFA, SVP Finance
Tel.: +49 (173) 5416390

For further technical information see IDEA’s website at www.idea-ag.de

Source: IDEA AG

Gilde Healthcare company LAVA Therapeutics announces exclusive worldwide license agreement with Seagen to advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta...
September 26, 2022

Gilde Healthcare portfolio company Moximed’s MISHA™ Knee System Achieves Superiority of Primary Endpoint in Pivotal Study

Moximed, a medical device company on a mission to improve the standard of care for people suffering with chronic knee pain due to osteoarthritis (OA), today announced clinical results presented at the 12th Orthopaedic Summit...
September 23, 2022

Gilde Healthcare portfolio company Amphista Therapeutics named as a “Fierce 15” biotech company of 2022

Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced that Fierce Biotech has named it as one of 2022’s Fierce 15 biotechnology companies, designating it as one of the most...
September 12, 2022